Mechanisms and pharmacology of neuropathic pain in multiple sclerosis

T. Iannitti, B. J. Kerr, B. K. Taylor

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The neuropathic pain of multiple sclerosis is quite prevalent and severely impacts quality of life. A few randomized, placebo-controlled, blinded clinical trials suggest that cannabis- and anticonvulsant-based treatments provide partial pain relief, but at the expense of adverse events. An even smaller, but emerging, number of translational studies are using rodent models of experimental autoimmune encephalomyelitis (EAE), which exhibit pain-like behaviors resembling those of Multiple sclerosis (MS) patients. These studies not only support the possible effectiveness of anticonvulsants, but also compel further clinical trials with serotonin–norepinephrine reuptake inhibitors, the immunosuppressant drug rapamycin, or drugs which interfere with glutamatergic neurotransmission. Future behavioral studies in EAE models are essential toward a new pharmacotherapy of multiple sclerosis pain.

Original languageEnglish (US)
Pages (from-to)75-97
Number of pages23
JournalCurrent Topics in Behavioral Neurosciences
Volume20
DOIs
StatePublished - 2014
Externally publishedYes

Bibliographical note

Publisher Copyright:
© Springer-Verlag Berlin Heidelberg 2014.

Keywords

  • Experimental autoimmune encephalomyelitis
  • Multiple sclerosis
  • Pain

Fingerprint

Dive into the research topics of 'Mechanisms and pharmacology of neuropathic pain in multiple sclerosis'. Together they form a unique fingerprint.

Cite this